Compare Incyte Corporation (INCY) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Plug Power Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Plug Power Inc trades at $2.16 (market cap $2.98B). The key difference: Incyte Corporation is far larger — about 7.8× Plug Power Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| INCY | PLUG | |
|---|---|---|
Market Cap | $23.11B | $2.98B |
Sector | Health | Industrials |
52-Week High | $118.52 | $4.14 |
52-Week Low | $67.38 | $1.40 |
Enterprise Value | $19.13B | $3.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Plug Power (PLUG) trades at $2.14, down 0.47% on the day, reflecting ongoing investor concerns about profitability despite recent contract wins. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal persistent losses with a -227.13% net income margin and negative cash flow. Recent news highlights a major 50MW Australian hydrogen project win, but operational challenges and dilution risks remain.
The outlook remains challenging with significant execution risks and cash burn, though analyst consensus suggests 36% upside to the $2.92 price target. Investment opportunity hinges on hydrogen adoption scaling faster than losses, while key risks include continued dilution, competitive pressure, and the company's ability to achieve profitability amid high debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
